I. INTRODUCTION: OVERVIEW OF PRIMARY MYELOFIBROSIS {#sec1-1}
==================================================

Myelofibrosis (MF) is a Philadelphia chromosome negative myeloproliferative neoplasm (MPN) clinically characterized by disease related constitutional symptoms, extramedullary hematopoiesis (EMH) especially splenomegaly, leukoerythroblastosis and variable degrees of cytopenia. Pathologically, the bone marrow (BM) of MF patients demonstrates atypical megakaryocytes, megakaryocytic hyperplasia, thickening and distortion of bony trabeculae and fibrosis \[[@ref1]\]. Clonal markers exemplified by cytogenetics can be helpful in diagnosis, prognosis and therapeutic stratification in myeloid malignancies. Key examples include t(9;22)(q34;q11) in chronic myeloid leukemia, 5q- in MDS with del5q abnormalities and inv(16)(p13;q22), t(16;16)(p13;q22), t(15;17)(q24;q21) and t(8;21)(q22;q22) in de novo acute myeloid leukemia. In MPN, the *JAK2* V617F mutation provided one of the most important genetic findings in the non-Philadelphia chromosome myeloid malignancies. Many non-JAK2 clonal markers have been recently identified in MF, including genes like *MPL* (exon 10)\[[@ref2]\], *TET2* \[[@ref3]\]*, ASXL1* \[[@ref4]\]*, IDH1/2* \[[@ref5]\]*, DNMT3A* \[[@ref6]\]*, EZH2* \[[@ref7]\]*, CBL* \[[@ref8]\] and *SH2B3* (*LNK*). Their exact role in the development of disease specific phenotypic features and clinical manifestations in MF is currently the subject of investigation but will likely provide new insight into disease specific mechanisms. For example, the ring sideroblast phenotype of MDS and even MF, mastocytosis and pure red cell aplasia patients can be explained by mutations in the *SF3B1* gene \[[@ref9]\]. Identification of phenotype-genotype associations specific to individual genetic mutations will hopefully translate to new therapeutic options for patients with MF that can lead to better clinical outcomes.

II. MOLECULAR MUTATIONS IN THE PATHOPHYSIOLOGY OF MYELOFIBROSIS {#sec1-2}
===============================================================

***JAK2 (exon 14):*** the discovery of mutations in the Janus kinase 2 (JAK2) signalling pathway opened a new perspective in the pathophysiology and treatment of MF \[[@ref10]\]. The frequency of JAK2V617F mutation ranges between 43-59% in MF. The most commonly detected mutation results in a guanine to thymine change at nucleotide 1849 \[[@ref11]\]. JAK2 is a member of JAK family (JAK1, JAK3 and TYK2) proteins which are cytoplasmic non-receptor tyrosine kinases with a significant function in cell proliferation and survival of hematopoietic stem cells (HSC). The JAK2V617F mutation is essential for self-reprogramming properties of HSC and it has been associated with some phenotypes of MF. Experiences in transgenic mice showed that, a low level of JAK2V617F load can induce essential thrombocytosis (ET)-type features, while the higher levels of mutant alleles can cause polycythemia vera (PV) and MF-like phenotypes \[[@ref12]\]. However, the presence of this mutation cannot consolidate all other MF related findings including cytopenia and the tendency of MF to transform to acute myeloid leukemia (AML) which is observed in 5-10% of patients with MF \[[@ref13]\]. Determination of the molecular basis for the constitutive activation of JAK2V617F is crucial for understanding its clinical implication. It has been elucidated that the position at amino acid 617 it is important for protein-protein interaction. Mutations at position 617 induce autophosphorylation, gene transcription and in vitro kinase activity of JAK2 \[[@ref14]\]. Recently, it was reported that activation of JAK2 can promoting the activation of three homodimeric myeloid receptors like EPO-receptor, MPL (TPO-receptor), and GM-CSF ([Figure 1](#fig001){ref-type="fig"})\[[@ref15]\].

Beside its role in mediating the signalling pathways of EPO and MPL, JAK2 signal can induce the over-expression of several oncogenes like LIM domain only 2 (LMO2) by an epigenetic regulation. JAK2 signal can re-model the chromatin structure by phosphorylating the histone H3Y41 and consequently blocking the recruitment of the repressor heterochromatin 1α leading to over-expression of LMO2 \[[@ref16]\].

***JAK2* (exon 12):** a gain-of-function mutation in exon 12 is detected in a small proportion (3-5%) of *JAK2* wild type (WT) MF patients. Murine studies have shown that mutations in this exon impacts erythrocyte proliferation \[[@ref17]\]. New alterations (deletions, insertions, substitutions) were found in positions 537 through 543. However, it is still unclear how these mutations can alter the function of *JAK2* \[[@ref17]\]. It has been elucidated that exon 12 links to SRC homology 2 (SH2) and JH2 domains of *JAK2*. Compared to *V617F* mutation, molecular alterations in exon 12 produce higher ligand-independent signaling and phosphorylation through JAK2 \[[@ref17]\]. In humans, these mutations are associated with younger age, lower level of erythropoietin, and lower predominance of erythroid myeloproliferation \[[@ref18]\]. Patients with polycythemia vera (PV) harboring mutations in exon 12 seem to be predisposed to transformation to MF.

***MPL* (Myeloproliferative Leukemia Virus):** the absence of *JAK2*V617F in some MF patients suggests the presence of alternative mechanism(s) that can activate the JAK/STAT pathway ([Figure 1](#fig001){ref-type="fig"})\[[@ref19]\]. *MPL* W515L/K can be detected in 5-10% in MF patients and appears to be a gain-of-function mutation \[[@ref20]\]. The *MPL* gene encodes a 635 amino acid protein called CD110. CD110 has 4 functional domains including a putative signal peptide, an extracellular domain, a transmembrane domain, and an intracellular domain \[[@ref22]\]. The ligand, thrombopoietin (TPO) can lead to dimerization of CD110 and subsequent downstream activation of the JAK-STAT pathway. The CD110-TPO is important in renewal of HSC and in the development and proliferation of megakaryocytes and platelets \[[@ref23]\]. The relationship between *MPL* W515L/K and the pathogenesis of MF are based on several important disease observations: 1) *MPL* W515L/K are found in the amphipathic KWQFP motif of CD110 which is important in preventing spontaneous activation of CD110, 2) Nude mice injected with *MPL*-transduced Ba/F3 cells developed subcutaneous tumors and splenomegaly \[[@ref24]\], and 3) BM transplantation assays conducted by injecting murine cells with W515L mutation led to features of ET and tendency of rapid evolution to MF \[[@ref25]\].

***TET2* (Ten Eleven Translocation-2):** *TET2* is a tumor suppressor gene located in a small region (0.35 Mb) of chromosome 4 (4q24). Mutations of this gene are frequently detected in various myeloid malignancies. In MPN, *TET2* has a frequency of 15-25% in PMF, 15-20% in post-PV MF, 10-15% in post-ET MF and 20-25% in MF that have progressed to AML \[[@ref26]\]. This molecular mutation can occur in conjunction with *JAK2*V617F mutation leading to a bi-clonal model or can precede the *JAK2* mutational event during disease formation \[[@ref26]\]. *TET2* mutations can lead to truncated proteins resulting in a total or partial loss-of-function. It has been postulated that molecular alterations in this gene may have been one of the first events in early hematopoiesis \[[@ref27]\]. In addition, the epigenetic role of *TET2* has been studied \[[@ref28]\]. *TET2* catalyzes the conversion of the 5-methylcytosine (5-MC) to 5-hydroxymethylcytosine (5-hMC) by oxidizing 5-MC. In patients carrying *TET2* mutations*,* the level of 5-hMC is lower than WT with variability across diseases (lower in myelodysplastic syndromes (MDS) and higher in AML)\[[@ref29]\]. In human hematopoiesis, knock-down of *TET2* resulted in increased monocytes differentiation and decreased erythroid proliferation \[[@ref16]\]. In a study conducted in our laboratory, *TET2* mutations were not present in *JAK2* WT MF patients in comparison to *JAK2* mutant counterpart \[[@ref30]\]. This observation was also reported by other investigators ([Figure 2](#fig002){ref-type="fig"})\[[@ref31]\].

***ASXL1* (Additional Sex Combs-like 1):** *ASXL1* is a polycomb gene required for long-term repression of the HOX genes. Genetically, in Drosophila, *Asx* gene behaves like an inducer of the trithorax complex. In general, polycomb genes are important in the manifestation of the bidirectional homeotic phenotypes suggesting their roles in the activation and silencing of *HOX* genes \[[@ref32]\]. *ASXL1,* is a potential epigenetic modifier, and mutations of this gene cam cause the loss of polycomb repressive complex 2 (PRC2)-mediated histone H3 lysine 27 (H3K27) tri-methylation which results in the transcriptional repression in hematopoietic cells \[[@ref33]\].

Loss of *ASXL1* can lead to the depletion of PRC2 and H3K27 involvement in myeloid leukemic cells which can cause the perturbation of polycomb-mediated gene silencing. It was elucidated that dysregulation of this interaction can make the cells prone to leukemia transformation \[[@ref33]\]. In addition, it has been shown to down-regulate the retinoic acid receptor signaling which can alter the transcription of particular genes \[[@ref34]\]. The frequency of *ASXL1* mutations in MF is about 15-20% albeit, in overlap syndromes particularly in chronic myelomonocytic leukemia (CMML) half of the patients acquire those mutations \[[@ref35]\]. It was reported that *ASXL1* mutations are usually mutually exclusive with *JAK2*V617F even though in one study *ASXL1* mutations were noted in conjunction with *JAK2*V617F or *TET2* mutations rather than *IDH1* \[[@ref35]\]. *ASXL1* mutations are usually seen in exon 12 and are missense, frame-shifts, and duplications in the case of the controversial variant (p.Gly646TrpfsX12)\[[@ref35]\].

***CBL* (Casitas B-cell Lymphoma):** *CBL* gene is located in the long arm of chromosome 11 (11q23.3) and encodes for a cytosolic protein with dual functionality; 1) down regulates tyrosine kinase signaling trigged by E3 ubiquitin ligase which leads to internalization and lysosomal/ proteosomal degradation and 2) modulation of downstream signaling of *JAK2* and *MPL* \[[@ref37]\]. In cell culture studies, a *CBL* mutation induces oncogenic phenotype and proliferation with activating the RAS-pathway in the absence of growth factor stimulation \[[@ref37]\]. *CBL* knockout mice manifested splenomegaly, HSC proliferation, and sensitivity to growth factors \[[@ref38]\]. The mutations of this gene were first described in AML as MLL-CBL fusion (MLL, exon 6 and CBL, exon 8) resulted in induction of the *FLT3* signaling. (38) *CBL* has been considered a tumor suppressor gene. The frequency of mutant *CBL* is about 15-20% and 3-6% in CMML and PMF, respectively \[[@ref39]\]. The mutations are mainly missense or in-frame deletions and usually coexist with *JAK2*, *TP53*, *FLT3* and *RUNX1* mutations \[[@ref40]\]. However, some studies have shown that at the time of disease progression, *CBL* mutations can occur after *JAK2*V617F mutation suggesting that two different cell lineages harbor these mutations \[[@ref37]\].

***IDH1/2* (Isocitrate Dehydrogenase 1/2):** *IDH1/2* are homodimeric NADP^+^ dependent enzymes involved in the conversion of isocitrate to α-ketoglutarate by oxidative decarboxylation prior to NADPH synthesis \[[@ref41]\]. Heterozygous mutations of these genes were first described in gliomas and secondary glioblastomas and then in AML \[[@ref42]\]. Mutations in *IDH1/2* can lead to an increase in NADPH-dependent reaction of α-ketoglutarate resulting in over production of α-hydroxyglutarate which is a potential toxic substance and conversely have a negative effect on the function of the TET2 protein ([Figure 2](#fig002){ref-type="fig"})\[[@ref44]\]. *IDH1/2* mutations usually involve the amino acid R132 and R172, respectively. The frequency of *IDH1/2* mutation is about 3-5%, 1-2%, and 10-20% in PMF, post-PV/ET MF and in MF cases evolving to AML \[[@ref45]\]. Furthermore, mutations in these genes are usually observed to be mutually exclusive from mutations of *JAK2*, *TET2*, and *MPL* \[[@ref39]\]. In addition, in gliomas the presence of *IDH1/2* mutations correlated to treatment response to chemotherapy. A study conducted in MPN has correlated the presence of a panel of molecular mutations including *IDH1/2* with a failure to response to treatment with PEG-interferon-α \[[@ref16]\]. Ultimately, *IDH1/2* mutations have been associated with transformation to AML even though it is not clear at this time where it falls in the hierarchy of mutational events in clonal evolution \[[@ref46]\].

***DNMT3A* (cytosine-5-methyltransferase 3-α):** the *DNMT3A* heterozygous mutations were initially described in AML and MDS with a frequency of 5-22% \[[@ref47]\]. However, in MF its frequency is lower (5 -12%)\[[@ref48]\]. This gene encodes a DNA methyltransferase that is essential in *de novo* methylation. Acquisition of mutations can cause loss-of-function resulting in homo-dimerization and activation of the protein, reduction of the activity of methyltransferase, and consequent increased cell proliferation \[[@ref48]\]. This gene can play a significant role in progression of MPN to AML in the presence of *JAK2* and *MPL* mutations. It has been showed that the time of mutational event acquisition reflects the disease course \[[@ref49]\]. In order to further dissect the role of this gene in MPN, a study described the isolation of different cellular lineages and the successive assessment of the cell type harboring high frequency of *DNMT3A* mutations. Mutations were identified with high frequency in CD14^+^ (monocytes) enriched fraction and with low frequency in CD3^+^ and CD19^+^ (T and B lymphocytes, respectively) suggesting that the aberrant clone does not occur in lymphoid lineages \[[@ref49]\]. Indeed, *DNMT3A* mutations are associated with over expression of other relevant genes in advanced myeloid malignancies \[[@ref48]\].

***SH2B3* (*LNK*):** the lymphocyte (*LNK* or *SH2B3*) adaptor protein is a member of the SH2B family and plays an important role in hematopoiesis and cytokine regulation. The protein encoded by this gene is a plasma adaptor component which binds to *JAK2* and inhibits the JAK/STAT signal transduction pathway \[[@ref50]\]. In addition, *LNK* negatively regulates the EPO receptor and *MPL* signaling resulting in the inhibition of the JAK-STAT pathway \[[@ref51]\]. In *JAK2*V617F mutant patients, *LNK* expression may increase which contributes to the developing of myeloproliferative phenotype \[[@ref14]\]. *LNK*-deficient mice showed a phenotype similar to MPN patients like splenomegaly, thrombocytosis, leukocytosis, abnormal megakaryocytes, and BM fibrosis \[[@ref52]\]. The prevalence of*LNK* mutations is low (\<5%) in MPN; however it is slightly higher (10-13%) in leukemic transformation of MF patients \[[@ref53]\]. Concomitant mutations in *JAK2*V617F and *LNK* were associated with disease evolution \[[@ref54]\]. In another study, LNK deficiency in mice increased cytokine independent- JAK-STAT signaling and also cooperates with *JAK2* activation in the development of a MPN like phenotype \[[@ref55]\].

***EZH2* (enhancer of zeste homolog 2)**: this gene is located in chromosome 7 (7q36.1) and belongs to the complex 2 of Polycomb, a mediator of transcriptional silencing and a regulator of multiple cellular process like proliferation, maturation, aging and hematopoietic cell plasticity \[[@ref56]\]. *EZH2* over-expression is noted in a variety of solid tumors like prostate and breast cancer and it has been reported to contribute to tumor aggressiveness and poor cellular differentiation \[[@ref57]\]. *EZH2* mutations appear to be a gain-of-function genetic change acting as a repressor by methylating the histone H3 on lysine 27 (H3K27) and consequently inactivating the chromatin \[[@ref58]\]. The frequency of *EZH2* mutations is approximately 12% in MF; however, mutations are not exclusively found in MPN since they are more frequent in MDS (2-6%) and MDS/MPN (\~15%). Clinically, *EZH2* mutations have been associated with poor prognosis \[[@ref7]\].

**RNA Splicing Machinery:** the recurrent mutations in genes encoding for different members of the RNA spliceosome machinery (*SF3B1*, *SRSF2*, *U2AF1* and *ZRSR2*) have been reported in myeloid malignancies in relatively high frequency (MDS with ring sideroblast \~86%, MDS without ring sideroblast \~44%, and in CMML \~55%)\[[@ref59]\]. All of the previously identified spliceosome genes are involved in the 3´-splice site recognition of a premature RNA. The U2 small nuclear RNA auxiliary factor 1 (*U2AF1)*, establishes a substantial interaction with the serine/ argentine domain of another splicing factor called *SRSF2* resulting in the exposure of the 3´-splice site and adjacent polypyrimidine tract. This synergism provides the possibility of actively recruiting also *SF3B1* in the formation of the splicing A complex and in the formation of a mature RNA ([Figure 3](#fig003){ref-type="fig"}). Molecular alterations in these genes can cause defect in splicing of downstream targets. *U2AF1* and *SRSF2* have been associated with leukemogenesis \[[@ref60]\]. The role of *SRSF2* in genomic stability has also been studied. Indeed, perturbation of the function of this gene resulted in double-strand DNA breaks \[[@ref60]\]. *SF3B1* mutations have been associated with good clinical outcomes and ring sideroblast formation in MDS \[[@ref9],[@ref61]\]. We reported the presence of an *SF3B1* mutation (K700E) in a patient with MF whose BM erythroid precursors also showed occasional ring sideroblast further supporting the role of *SF3B1* mutation on the pathogenesis of ring sideroblast formation even in non-MDS myeloid neoplasms \[[@ref62]\]. The clinical relevance of *ZRSR2* remains unclear due to the low frequency (3.1%) of mutations in MDS \[[@ref63]\]. In our laboratory we have been actively working in defining the frequency of the three most prevalent spliceosome genes in MDS (*SF3B1*, *U2AF1*, *SRSF2*) in a cohort of 130 patients with MF, finding a frequency of *SF3B1* (2%), *U2AF1* (8%), and *SRSF2* (17%)(Unpublished data). [Table 1](#table001){ref-type="table"} summarizes the frequency of all the genes discussed above.

III. THE IMPACT OF MOLECULAR MUTATIONS ON THE PHENOTYPES OF MYELOFIBROSIS {#sec1-3}
=========================================================================

MF usually affects patients with advanced age (\>65 years old) and usually experience constitutional symptoms (90%), splenomegaly (90%), fatigue (70%), anemia (60%), circulating blasts (50%), thrombocytopenia (30%), pulmonary hypertension (30-40%) and higher risk of thrombosis (10%)\[[@ref64]\].

\-**Anemia and other hematologic abnormalities.** There are many proposed mechanisms on the cause of anemia in MF patients and includes decrease bone marrow production due to decreased hematopoietic production sites in the BM due to fibrosis, splenic sequestration and consequent destruction of red cells in spleen, bleeding and autoimmune hemolysis. Yet, no distinctive molecular mutation has been proven to be the causative factor in the development of anemia in MF. Various studies that have looked at the clinical phenotypes of patients with MF with various molecular mutations have shown some some correlation between specific molecular subtypes and anemia. For example, patients with *MPL* and *TET2* mutations have lower Hgb levels \[[@ref26],[@ref66]\]. Conversely, observations from our laboratory showed that *JAK2* mutant patients who also harbor spliceosome mutations have lower Hgb levels (8.98 vs 10.5 g/dL) and slightly higher leukocyte counts (27.5 vs 20.5 x10^9^/L) compared to *JAK2* WT cases without spliceosome mutations (Unpublished data). Leukocytosis and thrombocytosis are other hematologic features of MF patients, the higher allele burden of *JAK2*V617F mutation has been associated with leukocytosis, reticulocytosis and splenomegaly while \[[@ref67]\] *MPL* mutations has been associated with thrombocytosis \[[@ref68]\].

**-Extramedullary hematopoiesis.** Splenomegaly is the most common type of extramedullary hematopoiesis (EMH) in MF; however the definitive mechanisms involved in the development of splenomegaly remains elusive. The prevailing hypothesis for the development of splenomegaly includes cytokine stimulation of the spleen, deposition of BM erythroid precursors in the spleen and extramedullary hematopoietic compensation to sustain blood production. Little is known regarding the effects of molecular mutations in the causation of splenomegaly. Among various molecular mutations, patients with MF who carry *JAK2* V617F and *CBL* mutations have enlarged spleens although the mechanisms whereby these mutations lead to EMH remain unclear \[[@ref69]\].

\-**Bone Marrow Fibrosis.** In MF, BM fibrosis is one of the important disease features and represents one of the major criteria for diagnosis. Fibrotic deposition can be detected using reticulin and/ or trichrome stains. It was alluded that fibrosis is the result of a reactive process of normal fibroblasts stimulated by aberrant cytokine activation resulting in the deposition of BM stromal fibers. Cytokines like transforming growth factor beta (TGF-β), platelet derived growth factor (PDGF,) and fibroblast growth factor (FGF) have been linked to the formation of fibrosis in BM \[[@ref70]\]. Disruption of *MPL* function can cause over-activation of the thrombopoietin-receptor, that can over-stimulate megakaryocytes to release several cytokines that can then contributes to fibrosis \[[@ref2]\].

IV. THE IMPACT OF MOLECULAR MUTATIONS ON PROGNOSIS OF MYELOFIBROSIS {#sec1-4}
===================================================================

A number of molecular mutations and genetic modifiers like single nucleotide polymorphisms have been described in MPN with some associated with poor prognosis and leukemia transformation \[[@ref72]\]. For instance, it has been shown that the presence of the A3669G polymorphism in an MF patient with *JAK2*V617F mutation is associated with shorter overall survival and blast transformation free survival \[[@ref73]\]. It has also been suggested that low *JAK2*V617F allele burden is associated with pancytopenia and higher susceptibility to infections which can result in lower overall survival \[[@ref74]\].

Additionally, presence of mutations in molecular markers like *IDH1/2, ASXL1, SRSF2* or *EZH* can independently predict shorter overall survival \[[@ref75]\]. Some of these mutations (eg, *IDH1/2* and *SRSF2*) have also been associated with inferior leukemia-free survival \[[@ref75]\].

Despite the high frequency of *JAK2*V617F and *TET2* mutations in MF, both genetic changes do not appear to affect survival outcomes \[[@ref34],[@ref69]\]. Conversely, MPL mutations are not associated with inferior outcomes. The existence of *EZH2* mutations in MDS was associated with poor overall survival and complex cytogenetic abnormalities. However, the same finding has not been established in MF \[[@ref76]\].

In our studies, the presence of *SRSF2* mutations contributed to a significant increase in the percentage of BM blasts and a higher incidence of progression to AML in MF patients (Unpublished data).

V. THE IMPACT OF MOLECULAR MARKERS ON RESPONSE TO TREATMENTS IN MYELOFIBROSIS {#sec1-5}
=============================================================================

The presence of molecular mutations can alter the response to therapies in MDS, MDS/MPN, and secondary AML \[[@ref77]\]. It was suggested that the presence of *TET2* mutations could have negative impact on response to *JAK* inhibitors \[[@ref78]\].

However, in other myeloid malignancies like MDS and AML, patients carrying *TET2* and *DNMT3A* mutations responded better to therapies specifically hypomethylating (HMA) agents \[[@ref79]\].

In MF, the presence of *JAK2*V617F mutation has been shown to be a predictor of better response to lenalidomide \[[@ref80]\].

VI. CONCLUSIONS {#sec1-6}
===============

In the JAK-inhibitor era, the management of some disease related features of MF has improved although there are still a lot of unmet needs including management of allele burden, treatment of cytopenias, and prevention of clonal evolution and therapy of patients who have evolved to AML. The discovery of molecular mutations has been expedited by next generation genomic technologies and this may lead to the identification of better therapeutic options for this disease similar to advancements being made in other hematologic malignancies \[[@ref79],[@ref81]\]v (unpublished data). It may also allow us to identify patients who may respond to treatments and those that are likely to develop resistance or relapse from their therapies. The discovery of novel genetic signatures and alternative signaling pathways will hold the key to understanding the basic help pathophysiology of MF and will open new avenues in the management of MF and other MPNs that can improve patient management and survival.
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![**JAK2 receptor signaling and activation of STAT pathway**. The binding of erythropoietin (EPO) to a receptor results in receptor dimerization of JAK2. This dimerization leads to phosphorylation of STAT3 and 5 and formation of stable homodimers and heterodimers which subsequently induce transcription of genes that regulate the cell proliferation and survival. The *JAK2V617F* mutation can cause the monotonous activation of STAT pathway in the absence of any other trigger. Furthermore, activation of MPL can initiate the downstream signaling cascade of JAK2 via recruitment of Src homology 2 (SH2) which can stimulate RAS protein and phosphoinositide-3 kinase (PI3K) leading to transcriptional activity of certain genes.](tm-08-53-g001){#fig001}

![**Krebs cycle to DNA methylation.** IDH1/2 wild-type enzymes convert isocitrate to α-ketoglutarate (αKG), a *TET2* substrate. IDH1/2 mutations result in neomorphic enzymes converting αKG to 2-hydroxyglutarate (2HG) which is an oncometabolite. 2HG can compromise the function of *TET2*. In addition, *TET2* and *DNMT3A* genes are involved in epigenetic transcriptional regulation by maintaining the DNA methylation during DNA replication and cell division.](tm-08-53-g002){#fig002}

![**RNA Splicing machinery.** RNA splicing is a mechanism in which non-coding regions (introns) are removed and coding regions (exons) strip to form a mature RNA. The GU dinucleotide at the 3' and terminal AG dinucleotide at the 5' ends serve as specific recognition sites. Several proteins forming complexes called: spliceosomes (U1, U2, SF1, U2AF) are involved in the removal of an intron lariat and assist in further steps in the formation of a mature messenger RNA.](tm-08-53-g003){#fig003}

###### 

FREQUENCY OF MOLECULAR MUTATIONS AND CORRELATION WITH DISEASE PHENOTYPES IN MYELOFIBROSIS

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene Symbol    Frequency (%)                                                                    Associated Disease-Phenotype/ Impact on Survival Outcomes   Studies
  -------------- -------------------------------------------------------------------------------- ----------------------------------------------------------- ---------------------------
  ***JAK2***     40-59                                                                            Higher Hgb\                                                 James et al, 2005\
                                                                                                  Leukocytosis\                                               Levine et al, 2005\
                                                                                                  BM Fibrosis                                                 Baxter et al, 2005\
                                                                                                                                                              Kralovics et al, 2005

  ***MPL***      5-10                                                                             Thrombocytosis\                                             Beer et al, 2008\
                                                                                                  Lower Hgb                                                   Boyd et al, 2010\
                                                                                                                                                              Chaligne et al, 2008

  ***TET2***     15-20                                                                            Anemia                                                      Vannucchi et al, 2013\
                                                                                                                                                              Brecqueville et al, 2012\
                                                                                                                                                              Delhommeau et al, 2009

  ***LNK***      \<5                                                                              BM Fibrosis                                                 Ha et al, 2011\
                                                                                                                                                              St et al , 2010\
                                                                                                                                                              Pardanani et al, 2010

  ***DNMT3A***   5-12                                                                             Poor Prognosis                                              Vannucchi et al, 2013\
                                                                                                                                                              Stegelmann et al, 2011\
                                                                                                                                                              Abdel-Wahab et al, 2011

  ***IDH1/2***   \<5                                                                              Poor prognosis                                              Vannucchi et al, 2013\
                                                                                                                                                              Brecqueville et al, 2012\
                                                                                                                                                              Tefferi et al, 2010

  ***ASXL1***    17-25                                                                            BM Fibrosis/ Poor Prognosis                                 Brecqueville et al, 2012\
                                                                                                                                                              Ricci et al, 2012\
                                                                                                                                                              Stein et al, 2011

  ***CBL***      \<5                                                                              BM Fibrosis                                                 Schnittger et al, 2012\
                                                                                                                                                              Brecqueville et al, 2012\
                                                                                                                                                              Vainchenker et al, 2011

  ***EZH2***     5-8                                                                              Poor prognosis                                              Score et al, 2012\
                                                                                                                                                              Guglielmelli et al, 2011\
                                                                                                                                                              Ernst et al, 2010

  ***SF3B1***    2-7                                                                              Ring sideroblast/ Good prognosis                            Visconte et al, 2012

  ***U2AF1***    5-9                                                                              Poor prognosis                                              Lasho et al, 2012

  ***SRSF2***    15-25                                                                            Anemia/ Poor prognosis                                      Lehmann et al, 2013\
                                                                                                                                                              Vannucchi et al, 2013\
                                                                                                                                                              Lasho et al, 2012

  ***ZRSR2***    \<5[^§^](#tfn001){ref-type="table-fn"}; 1.9[^†^](#tfn002){ref-type="table-fn"}   Unknown                                                     Thol et al, 2012\
                                                                                                                                                              Yoshida et al, 2011
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Table Legend:** Summary of the frequencies, disease-phenotypes, and impact on survival outcomes of molecular mutations in Myelofibrosis.

^§^the frequency refers to Myelodysplastic syndromes.

^†^this frequency refers to a study conducted with whole exome sequencing

**Abbreviations.** Hgb, hemoglobin; BM, bone marrow.
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